DFTX is trading 6.9% down at $34.11 in pre-market action, pulling back from yesterday's significant gains following the announcement of a ~$500 million equity offering.
- The stock is easing back after a massive jump in the previous session driven by positive Phase 3 clinical trial data.
- The newly announced capital raise pressured shares in after-hours trading as investors weigh the dilutive impact against the strong clinical results.
- The offering aims to capitalize on the recent price surge to strengthen the company's balance sheet following the successful trial outcome.